Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

(Stock code: 6488)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board SBI Holdings, Inc.

Yoshitaka Kitao

Representative Director,
President & Chief Executive Officer

Japan, 11 November 2013

As of the date of this announcement, the executive Directors are Mr. Yoshitaka Kitao, Mr. Taro Izuchi, Mr. Takashi Nakagawa, Mr. Tomoya Asakura, Mr. Shumpei Morita, Mr. Noriaki Maruyama and Mr. Peilung Li, the non-executive Directors are Mr. Masato Takamura, Mr. Hiroshi Tasaka and Mr. Teruhide Sato and the independent non-executive Directors are Mr. Masaki Yoshida, Mr. Kiyoshi Nagano, Mr. Keiji Watanabe, Mr. Akihiro Tamaki and Mr. Masanao Marumono.

Strategic Alliance with Fudan Forward and the New Hope Group

for Sales of 5-ALA Products in China

We are pleased to inform you that SBI Holdings, Inc. ("SBIH") has reached a basic agreement with New Hope

Group CO., LTD. (Head Office: Chengdu, People's Republic of China; "New Hope Group"), China's largest

privately owned agribusiness company, and Shanghai Fudan Forward Commercial Property Investment

Company Limited (Head Office: Shanghai, People's Republic of China; "Fudan Forward"), a company under

the aegis of Fudan University. This agreement relates to forming a strategic alliance for sales of

pharmaceuticals, health foods and other products (including cosmetics) containing 5-aminolevulinic acid

("5-ALA"*) in China.

Under this strategic alliance, as the first step, SBIH is planning to expand the sales of health foods containing

5-ALA as soon as necessary licenses are obtained, by leveraging the current sales channel of the affiliated

health foods companies of Fudan Forward. The health foods containing 5-ALA planned to be sold are those

manufactured by Suzhou Yian Biotech Co., Ltd., which manufacturing license is scheduled to be obtained, and

also those imported from Japan, subject to the acquisition of a license for selling imported goods. Furthermore,

by utilizing the New Hope Group's nationwide network in China, sales of fertilizers and forages containing

5-ALA are scheduled.

For the second step, after the awareness of 5-ALA in China has increased and the sales figures of the products

have reached a certain level, the New Hope Group, Fudan Forward and SBIH will jointly establish a sales

company specialized in products containing 5-ALA.

SBIH will also consider sales expansion in the field of pharmaceuticals and cosmetics in China after obtaining

necessary licenses, by leveraging the existing networks of the New Hope Group and Fudan Forward, and

establishing new sales channels.

Meanwhile, the future impact on SBIH's consolidated financial results is yet to be determined at present.

The SBI Group will continue to explore various possibilities of utilizing 5-ALA, and proactively promote joint

business development with partners both inside and outside Japan, hoping to contribute to the health of as many

people as possible in the world.

* 5-aminolevulinic acid (5-ALA): An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.

For further information, please contact:

SBI Holdings, Inc. Corporate Communications Dept., Tel: +81 3 6229-0126